Pharmaceutical LSD (MM120) shows single-dose benefits for generalized anxiety disorder by promoting neuroplasticity and reducing rigid thought

Pharmaceutical LSD known as MM120 shows single-dose potential for generalized anxiety disorder (GAD), aiming to reduce persistent, out-of-proportion anxiety that often responds poorly to standard medications. UCSF neuroscientist Jennifer Mitchell, PhD, reports that MM120 is designed to promote neuroplasticity and improve communication between brain regions linked to rigid thought patterns. In earlier phase results referenced from JAMA, a single dose produced symptom reductions over about 12 weeks that were large enough to potentially shift moderate GAD toward a mild range for some participants. The work also discusses side effects observed during closely monitored clinical trial follow-up, including hallucinations, visual distortions, nausea, and headache, with nausea mitigated via a light breakfast and proactive anti-nausea medication. The research highlights recruitment challenges for people with disabling symptoms who may be reluctant to leave home, emphasizing careful clinician screening and rapport building.